

Antal Tamás Zemplényi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2479484/publications.pdf>

Version: 2024-02-01

19
papers

263
citations

1040056

9
h-index

996975

15
g-index

27
all docs

27
docs citations

27
times ranked

365
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer. <i>European Journal of Cancer Care</i> , 2018, 27, e12430.	1.5	47
2	The effect of performance-volume limit on the DRG based acute care hospital financing in Hungary. <i>Health Policy</i> , 2014, 115, 152-156.	3.0	34
3	Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines. <i>Pharmacoeconomics</i> , 2020, 38, 1055-1070.	3.3	33
4	Direct healthcare cost of schizophrenia – European overview. <i>European Psychiatry</i> , 2018, 48, 79-92.	0.2	31
5	Defining good health and care from the perspective of persons with multimorbidity: results from a qualitative study of focus groups in eight European countries. <i>BMJ Open</i> , 2018, 8, e021072.	1.9	21
6	Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 105-113.	1.4	11
7	Implementation of palliative care consult Service in Hungary – integration barriers and facilitators. <i>BMC Palliative Care</i> , 2020, 19, 41.	1.8	11
8	Cost-effectiveness analysis of invasive EEG monitoring in drug-resistant epilepsy. <i>Epilepsy and Behavior</i> , 2021, 114, 107488.	1.7	11
9	Planning, implementation and operation of a personalized patient management system for subjects with first suspect of cancer (OnkoNetwork): system description based on a qualitative study. <i>BMC Health Services Research</i> , 2019, 19, 131.	2.2	10
10	Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges. <i>Frontiers in Public Health</i> , 2020, 8, 612410.	2.7	9
11	Regulatory and HTA early dialogues in medical devices. <i>Health Policy</i> , 2021, 125, 1322-1329.	3.0	8
12	Recurrent acute pancreatitis prevention by the elimination of alcohol and cigarette smoking (REAPPEAR): protocol of a randomised controlled trial and a cohort study. <i>BMJ Open</i> , 2022, 12, e050821.	1.9	8
13	Using real-world evidence in healthcare from Western to Central and Eastern Europe: a review of existing barriers. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 905-913.	1.4	7
14	Development of transferability guidance for integrated care models with special focus on Central and Eastern European countries. <i>Croatian Medical Journal</i> , 2020, 61, 252-259.	0.7	5
15	Implementation of coverage with evidence development schemes for medical devices: A decision tool for late technology adopter countries. <i>Health Economics (United Kingdom)</i> , 2022, , .	1.7	5
16	Can cost-effectiveness principles be ignored in urgent times?. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 7-9.	1.4	3
17	Early palliative care associated with lower costs for adults with advanced cancer: evidence from Hungary. <i>European Journal of Cancer Care</i> , 2021, 30, e13473.	1.5	2
18	Survey of workflow and cost implications of decommissioning regarding the Falsified Medicines Directive in Hungarian hospital pharmacies. <i>BMJ Open</i> , 2021, 11, e047193.	1.9	1

#	ARTICLE	IF	CITATIONS
19	Should Hungary Pay More for a QALY Gain than Higher-Income Western European Countries?. Applied Health Economics and Health Policy, 2022, 20, 291-303.	2.1	1